{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:19:22Z","timestamp":1787008762804,"version":"build-2736575974"},"reference-count":81,"publisher":"Oxford University Press (OUP)","issue":"Supplement_A","license":[{"start":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T00:00:00Z","timestamp":1551139200000},"content-version":"vor","delay-in-days":25,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"National Institutes of Health and European Union"},{"name":"Janssen"},{"name":"Vifor"},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Vascular Dynamics"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,2,1]]},"DOI":"10.1093\/eurheartj\/suy030","type":"journal-article","created":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T06:04:31Z","timestamp":1551161071000},"page":"A20-A27","source":"Crossref","is-referenced-by-count":24,"title":["Barriers to guideline mandated renin\u2013angiotensin inhibitor use: focus on hyperkalaemia"],"prefix":"10.1093","volume":"21","author":[{"given":"Shilpa","family":"Vijayakumar","sequence":"first","affiliation":[{"name":"Department of Medicine, Stony Brook University, 101 Nicolls Road, Stony Brook, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Mississippi, 2500 North State Street, Jackson, MS, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George L","family":"Bakris","sequence":"additional","affiliation":[{"name":"Department of Medicine, Comprehensive Hypertension Center, The University of Chicago Medicine, 5481 S. Maryland Avenue MC 1027, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,2,26]]},"reference":[{"key":"key\n\t\t\t\t2019022808504536600_suy030-B1","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1161\/CIRCULATIONAHA.117.030576","article-title":"Long-term potassium monitoring and dynamics in heart failure and risk of mortality","volume":"137","author":"Nunez","year":"2018","journal-title":"Circulation"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B2","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1159\/000479802","article-title":"Association of serum potassium with all-cause mortality in patients with and without heart failure, chronic kidney disease, and\/or diabetes","volume":"46","author":"Collins","year":"2017","journal-title":"Am J Nephrol"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B3","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1001\/archinternmed.2009.132","article-title":"The frequency of hyperkalemia and its significance in chronic kidney disease","volume":"169","author":"Einhorn","year":"2009","journal-title":"Arch Intern Med"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B4","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.amjcard.2012.01.367","article-title":"Predictors of hyperkalemia and death in patients with cardiac and renal disease","volume":"109","author":"Jain","year":"2012","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B5","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","article-title":"Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study","volume":"351","author":"Juurlink","year":"2004","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B6","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMra035279","article-title":"Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system","volume":"351","author":"Palmer","year":"2004","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B7","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.semnephrol.2014.04.008","article-title":"Prediction and management of hyperkalemia across the spectrum of chronic kidney disease","volume":"34","author":"Lazich","year":"2014","journal-title":"Semin Nephrol"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B8","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.3109\/0886022X.2012.717478","article-title":"Major barriers against renin-angiotensin-aldosterone system blocker use in chronic kidney disease stages 3-5 in clinical practice: a safety concern?","volume":"34","author":"Yildirim","year":"2012","journal-title":"Ren Fail"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B9","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/B978-0-12-803247-3.00002-7","volume-title":"Textbook of Nephro-Endocrinology","author":"Ko","year":"2018","edition":"2"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B10","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":". 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B11","first-page":"S212","article-title":"Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors","volume":"21","author":"Epstein","year":"2015","journal-title":"Am J Manag Care"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B12","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1161\/CIRCULATIONAHA.117.031422","article-title":"Sodium\/glucose cotransporter 2 inhibitors in patients with diabetes mellitus and chronic kidney disease: turning the page","volume":"137","author":"Plutzky","year":"2018","journal-title":"Circulation"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B13","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1056\/NEJMra1313341","article-title":"An integrated view of potassium homeostasis","volume":"373","author":"Gumz","year":"2015","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B14","doi-asserted-by":"crossref","first-page":"b4114.","DOI":"10.1136\/bmj.b4114","article-title":"Hyperkalaemia","volume":"339","author":"Nyirenda","year":"2009","journal-title":"BMJ"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B15","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.2215\/CJN.08580813","article-title":"Regulation of potassium homeostasis","volume":"10","author":"Palmer","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B16","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s00467-010-1699-3","article-title":"Pathogenesis, diagnosis and management of hyperkalemia","volume":"26","author":"Lehnhardt","year":"2011","journal-title":"Pediatr Nephrol"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B17","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/ejhf.444","article-title":"Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease","volume":"18","author":"Bramlage","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B18","first-page":"1571","article-title":"New agents for hyperkalemia","volume":"372","author":"Packham","year":"2015","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B19","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/j.jacc.2012.07.048","article-title":"Influence of baseline and worsening renal function on efficacy of spironolactone in patients With severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study)","volume":"60","author":"Vardeny","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B20","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/00000441-197105000-00007","article-title":"Functional impairment in chronic renal disease. 3. Studies of potassium excretion","volume":"261","author":"Gonick","year":"1971","journal-title":"Am J Med Sci"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B21","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/nrneph.2014.168","article-title":"Management of hyperkalaemia in chronic kidney disease","volume":"10","author":"Kovesdy","year":"2014","journal-title":"Nat Rev Nephrol"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B22","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1001\/archinte.1977.03630190010005","article-title":"Nonuremic diabetic hyperkalemia. Possible role of insulin deficiency","volume":"137","author":"DeFronzo","year":"1977","journal-title":"Arch Intern Med"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B23","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1093\/eurheartj\/ehv565","article-title":"Improving outcomes in heart failure: a personal perspective","volume":"36","author":"McMurray","year":"2015","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B24","doi-asserted-by":"crossref","first-page":"e003529.","DOI":"10.1161\/CIRCHEARTFAILURE.116.003529","article-title":"Thirty years of evidence on the efficacy of drug treatments for chronic heart failure with reduced ejection fraction: a network meta-analysis","volume":"10","author":"Burnett","year":"2017","journal-title":"Circ Heart Fail"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B25","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.cardfail.2017.04.014","article-title":"2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America","volume":"23","author":"Yancy","year":"2017","journal-title":"J Card Fail"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B26","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/ejhf.496","article-title":"Use of evidence-based therapy and survival in heart failure in Sweden 2003-2012","volume":"18","author":"Thorvaldsen","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B27","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1093\/eurjhf\/hft134","article-title":"Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry","volume":"15","author":"Maggioni","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B28","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jacc.2012.08.1019","article-title":"Temporal trends and predictors in the use of aldosterone antagonists post-acute myocardial infarction","volume":"61","author":"Rassi","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B29","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1001\/jama.2009.1493","article-title":"Use of aldosterone antagonists in heart failure","volume":"302","author":"Albert","year":"2009","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B30","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1001\/archinte.158.8.917","article-title":"Hyperkalemia in hospitalized patients: causes, adequacy of treatment, and results of an attempt to improve physician compliance with published therapy guidelines","volume":"158","author":"Acker","year":"1998","journal-title":"Arch Intern Med"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B31","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1159\/000013599","article-title":"Predictors of the development of hyperkalemia in patients using angiotensin-converting enzyme inhibitors","volume":"20","author":"Ahuja","year":"2000","journal-title":"Am J Nephrol"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B32","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archinte.158.1.26","article-title":"Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry?","volume":"158","author":"Reardon","year":"1998","journal-title":"Arch Intern Med"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B33","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1532-5415.2011.03818.x","article-title":"Metabolic complications in elderly adults with chronic kidney disease","volume":"60","author":"Drawz","year":"2012","journal-title":"J Am Geriatr Soc"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B34","doi-asserted-by":"crossref","first-page":"c8","DOI":"10.1159\/000329511","article-title":"Association of hypo- and hyperkalemia with disease progression and mortality in males with chronic kidney disease: the role of race","volume":"120","author":"Hayes","year":"2012","journal-title":"Nephron Clin Pract"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B35","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.2215\/CJN.01150112","article-title":"Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic","volume":"7","author":"Sarafidis","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B36","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B37","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.cardfail.2010.01.001","article-title":"Renal function in outpatients with chronic heart failure","volume":"16","author":"Waldum","year":"2010","journal-title":"J Card Fail"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B38","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.jacc.2013.11.031","article-title":"Current evidence on treatment of patients with chronic systolic heart failure and renal insufficiency: practical considerations from published data","volume":"63","author":"Damman","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B39","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B40","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1161\/CIRCHEARTFAILURE.114.001104","article-title":"Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist","volume":"7","author":"Vardeny","year":"2014","journal-title":"Circ Heart Fail"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B41","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/CIRCHEARTFAILURE.113.000792","article-title":"Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF)","volume":"7","author":"Rossignol","year":"2014","journal-title":"Circ Heart Fail"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B42","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/ehjcvp\/pvv026","article-title":"Short-term mortality risk of serum potassium levels in acute heart failure following myocardial infarction","volume":"1","author":"Krogager","year":"2015","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B43","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.jacc.2016.06.060","article-title":"Hyperkalemia in heart failure","volume":"68","author":"Sarwar","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B44","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/164_2017_25","article-title":"Role of hyperkalemia in heart failure and the therapeutic use of potassium binders","volume":"243","author":"Sarwar","year":"2017","journal-title":"Handb Exp Pharmacol"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B45","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1053\/j.jrn.2016.02.005","article-title":"Nutrient non-equivalence: does restricting high-potassium plant foods help to prevent hyperkalemia in hemodialysis patients?","volume":"26","author":"St-Jules","year":"2016","journal-title":"J Ren Nutr"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B46","first-page":"730","article-title":"Foods high in potassium","volume":"14","author":"McRae","year":"1979","journal-title":"Hosp Pharm"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B47","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2146\/ajhp150457","article-title":"Emerging therapies for the management of chronic hyperkalemia in the ambulatory care setting","volume":"73","author":"Henneman","year":"2016","journal-title":"Am J Health Syst Pharm"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B48","doi-asserted-by":"crossref","first-page":"R225.","DOI":"10.1186\/cc11872","article-title":"Severe hyperkalemia requiring hospitalization: predictors of mortality","volume":"16","author":"An","year":"2012","journal-title":"Crit Care"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B49","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1681\/ASN.V981535","article-title":"Hyperkalemia: a potential silent killer","volume":"9","author":"Weiner","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B50","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/0002-9149(63)90255-8","article-title":"Electrolytes and the electrocardiogram","volume":"12","author":"Surawicz","year":"1963","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B51","first-page":"s307","article-title":"The burden of hyperkalemia in patients with cardiovascular and renal disease","volume":"21","author":"Dunn","year":"2015","journal-title":"Am J Manag Care"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B52","first-page":"697","article-title":"Effect of calcium to reverse the electrocardiographic effects of hyperkalemia in the isolated rat heart: a prospective, dose-response study","volume":"22","author":"Bisogno","year":"1994","journal-title":"Crit Care Med"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B53","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S0140-6736(64)90797-4","article-title":"Emergency treatment of hyperkalaemia","volume":"1","author":"Chamberlain","year":"1964","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B54","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/ki.1990.284","article-title":"Albuterol and insulin for treatment of hyperkalemia in hemodialysis patients","volume":"38","author":"Allon","year":"1990","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B55","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1097\/CCM.0b013e31818f222b","article-title":"Management of severe hyperkalemia","volume":"36","author":"Weisberg","year":"2008","journal-title":"Crit Care Med"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B56","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/ki.1977.122","article-title":"Correction of hyperkalemia by bicarbonate despite constant blood pH","volume":"12","author":"Fraley","year":"1977","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B57","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1046\/j.1525-139X.2001.00087.x","article-title":"Hyperkalemia in dialysis patients","volume":"14","author":"Ahmed","year":"2001","journal-title":"Semin Dial"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B58","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1159\/000167176","article-title":"Variability in potassium removal by hemodialysis","volume":"6","author":"Sherman","year":"1986","journal-title":"Am J Nephrol"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B59","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/0140-6736(92)90008-Q","article-title":"Ventricular arrhythmias and four-year mortality in haemodialysis patients. Gruppo Emodialisi e Patologie Cardiovascolari","volume":"339","author":"Sforzini","year":"1992","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B60","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1046\/j.1523-1755.2001.00806.x","article-title":"Cardiac arrest and sudden death in dialysis units","volume":"60","author":"Karnik","year":"2001","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B61","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1053\/j.ajkd.2004.03.003","article-title":"K\/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease","volume":"43","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B62","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1161\/HYPERTENSIONAHA.115.04889","article-title":"New potassium binders for the treatment of hyperkalemia: current data and opportunities for the future","volume":"66","author":"Pitt","year":"2015","journal-title":"Hypertension"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B63","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1001\/archinte.160.6.870","article-title":"Herbal interactions with cardiac drugs","volume":"160","author":"Cheng","year":"2000","journal-title":"Arch Intern Med"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B64","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/j.1939-1676.2010.0488.x","article-title":"Correction of hyperkalemia in dogs with chronic kidney disease consuming commercial renal therapeutic diets by a potassium-reduced home-prepared diet","volume":"24","author":"Segev","year":"2010","journal-title":"J Vet Intern Med"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B65","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1007\/s00424-017-1990-2","article-title":"Severe hyperkalemia is rescued by low-potassium diet in renal betaENaC-deficient mice","volume":"469","author":"Boscardin","year":"2017","journal-title":"Pflugers Arch"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B66","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S0002-9343(01)00688-X","article-title":"Drug-induced hyperkalemia","volume":"112","author":"Pantanowitz","year":"2002","journal-title":"Am J Med"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B67","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s11606-009-1228-x","article-title":"Diabetes and drug-associated hyperkalemia: effect of potassium monitoring","volume":"25","author":"Raebel","year":"2010","journal-title":"J Gen Intern Med"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B68","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s11897-017-0341-0","article-title":"Treatment of hyperkalemia in heart failure","volume":"14","author":"DeFilippis","year":"2017","journal-title":"Curr Heart Fail Rep"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B69","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1345\/aph.19326","article-title":"Fludrocortisone for the treatment of heparin-induced hyperkalemia","volume":"34","author":"Sherman","year":"2000","journal-title":"Ann Pharmacother"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B70","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1016\/j.transproceed.2011.07.006","article-title":"Fludrocortisone is effective in the management of tacrolimus-induced hyperkalemia in liver transplant recipients","volume":"43","author":"Dick","year":"2011","journal-title":"Transplant Proc"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B71","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1053\/j.ajkd.2006.01.014","article-title":"A randomized controlled trial of fludrocortisone for the treatment of hyperkalemia in hemodialysis patients","volume":"47","author":"Kaisar","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B72","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1093\/ndt\/gfm386","article-title":"Effect of fludrocortisone acetate on reducing serum potassium levels in patients with end-stage renal disease undergoing haemodialysis","volume":"22","author":"Kim","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B73","first-page":"43","article-title":"Potassium-binding agents for the clinical management of hyperkalemia","volume":"41","author":"Chaitman","year":"2016","journal-title":"P T"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B74","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1681\/ASN.2010010079","article-title":"Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective?","volume":"21","author":"Sterns","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B75","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ijcard.2016.04.127","article-title":"New approaches to hyperkalemia in patients with indications for renin angiotensin aldosterone inhibitors: considerations for trial design and regulatory approval","volume":"216","author":"Zannad","year":"2016","journal-title":"Int J Cardiol"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B76","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1410853","article-title":"Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors","volume":"372","author":"Weir","year":"2015","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B77","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/jama.2015.7446","article-title":"Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B78","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.amjmed.2017.11.011","article-title":"Effect of patiromer on hyperkalemia recurrence in older chronic kidney disease patients taking RAAS inhibitors","volume":"131","author":"Weir","year":"2018","journal-title":"Am J Med"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B79","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/ehf2.12292","article-title":"Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes\/angiotensin receptor blockers: results from AMETHYST-DN","volume":"5","author":"Pitt","year":"2018","journal-title":"ESC Heart Fail"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B80","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1411487","article-title":"Sodium zirconium cyclosilicate in hyperkalemia","volume":"372","author":"Packham","year":"2015","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019022808504536600_suy030-B81","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1001\/jama.2014.15688","article-title":"Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial","volume":"312","author":"Kosiborod","year":"2014","journal-title":"JAMA"}],"container-title":["European Heart Journal Supplements"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/21\/Supplement_A\/A20\/27994225\/suy030.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T12:45:44Z","timestamp":1662986744000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article\/21\/Supplement_A\/A20\/5364190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,1]]},"references-count":81,"journal-issue":{"issue":"Supplement_A","published-online":{"date-parts":[[2019,2,26]]},"published-print":{"date-parts":[[2019,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/suy030","relation":{},"ISSN":["1520-765X","1554-2815"],"issn-type":[{"value":"1520-765X","type":"print"},{"value":"1554-2815","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,2]]},"published":{"date-parts":[[2019,2,1]]}}}